These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 765862)

  • 21. [Are there any changes in CSF IgG levels in multiple sclerosis treated for long periods with an immunosuppressive agent (azathioprine)?].
    Oger J; Cloarec L; Chatel M; Sabouraud O
    Nouv Presse Med; 1973 Feb; 2(7):443. PubMed ID: 4631717
    [No Abstract]   [Full Text] [Related]  

  • 22. [Oligoclonal and polyclonal gamma globulin bands in the cerebrospinal fluid in subacute sclerosing panencephalitis, multiple sclerosis and congenital infections of the central nervous system].
    Cendrowski W
    Postepy Hig Med Dosw; 1987; 41(6):663-72. PubMed ID: 3330223
    [No Abstract]   [Full Text] [Related]  

  • 23. Therapeutic trials of multiple sclerosis and intrathecal IgG production.
    Wender M; Tokarz E; Michalowska G; Wajgt A
    Ital J Neurol Sci; 1986 Apr; 7(2):205-8. PubMed ID: 3013800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Moving on to second-line therapies in pediatric MS: Immunosuppression with cyclophosphamide.
    Yeh EA; Weinstock-Guttman B
    Neurology; 2009 Jun; 72(24):2064-5. PubMed ID: 19439721
    [No Abstract]   [Full Text] [Related]  

  • 25. [Guidelines for drug treatment of multiple sclerosis].
    Kollegger H; Vass K; Marschall I; Koch G; Deecke L
    Wien Klin Wochenschr; 1993; 105(16):443-52. PubMed ID: 7692677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The need for a new strategy for the treatment of multiple sclerosis.
    Davison AN
    J Neurol; 1988 Jul; 235(6):327-9. PubMed ID: 3171613
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunosuppressive therapy in multiple sclerosis.
    Edan G
    Neurol Sci; 2005 May; 26 Suppl 1():S18. PubMed ID: 15883680
    [No Abstract]   [Full Text] [Related]  

  • 28. [Immunosuppressive medication in multiple sclerosis].
    García Merino JA
    Rev Neurol; 2002 Dec 16-31; 35(12):1154-8. PubMed ID: 12497298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proceedings: Intensive immunosuppression in multiple sclerosis.
    Lance EM; Abbosh J; Kremer M; Jones V; Knight S; Medawar P
    Neurology; 1975 May; 25(5):491. PubMed ID: 1169713
    [No Abstract]   [Full Text] [Related]  

  • 30. [Methodologic and ethical implications of immunosuppressive therapy in multiple sclerosis].
    Szobor A
    Orv Hetil; 1984 Mar; 125(11):673. PubMed ID: 6700975
    [No Abstract]   [Full Text] [Related]  

  • 31. Glatiramer in the treatment of multiple sclerosis.
    Rizvi SA; Kim E; Moodie J
    Int J Nanomedicine; 2006; 1(3):283-9. PubMed ID: 17717969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
    Banwell B; Tremlett H
    Neurology; 2005 Mar; 64(5):778-9. PubMed ID: 15753408
    [No Abstract]   [Full Text] [Related]  

  • 33. Quinpramine: revival of old anti-inflammatory principles in multiple sclerosis?
    Haghikia A; Gold R
    Exp Neurol; 2009 Jun; 217(2):240-1. PubMed ID: 19361499
    [No Abstract]   [Full Text] [Related]  

  • 34. The Janus face of CNS-directed autoimmune response: a therapeutic challenge.
    Kappos L; Duda P
    Brain; 2002 Nov; 125(Pt 11):2379-80. PubMed ID: 12390965
    [No Abstract]   [Full Text] [Related]  

  • 35. [Therapy of multiple sclerosis].
    Simó M
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):23-6. PubMed ID: 19731815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spreading of autoimmunity from central to peripheral myelin: two cases of clinical association between multiple sclerosis and chronic inflammatory demyelinating polyneuropathy.
    Falcone M; Scalise A; Minisci C; Romito D; Cancelli I; Gigli GL
    Neurol Sci; 2006 Apr; 27(1):58-62. PubMed ID: 16688601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blockade of chemokine signaling in patients with multiple sclerosis.
    Zipp F; Hartung HP; Hillert J; Schimrigk S; Trebst C; Stangel M; Infante-Duarte C; Jakobs P; Wolf C; Sandbrink R; Pohl C; Filippi M;
    Neurology; 2006 Nov; 67(10):1880-3. PubMed ID: 17130431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunosuppressive treatment of multiple sclerosis (review of the literature].
    Neretin VIa; Kir'iakov VA; Sapfirova VA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(2):119-26. PubMed ID: 2160156
    [No Abstract]   [Full Text] [Related]  

  • 39. [Multiple sclerosis and measles virus].
    Panelius M
    Duodecim; 1971; 87(22):1462-4. PubMed ID: 5136499
    [No Abstract]   [Full Text] [Related]  

  • 40. Relevance of immunological variables in neuroborreliosis and multiple sclerosis.
    Bednárová J; Stourac P; Adam P
    Acta Neurol Scand; 2005 Aug; 112(2):97-102. PubMed ID: 16008535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.